Ascendis Pharma A/S Cash Flow Statement Analysis

Operating, investing, and financing activities in millions EUR

Scroll to see more
Cash flow statement showing operating, investing, and financing activities for Ascendis Pharma A/S (ASND) - Annual data in millions EUR
BreakdownFY 2024FY 2023FY 2022FY 2021FY 2020
Period EndingDec 2024Dec 2023Jan 2023Dec 2021Dec 2020
Operating Activities
Net Income-378.08-481.45-583.19-383.58-418.96
Depreciation & Amortization17.7118.9117.5114.959.45
Deferred Income Tax4.847.305.38-0.37-0.22
Stock Based Compensation95.5166.6664.1866.8353.17
Change in Working Capital-107.16-99.79-12.47-47.72-0.96
Change in Accounts Receivable-118.61-32.77-11.53-6.66-2.00
Change in Inventory-86.68-78.26-55.27-75.410.00
Change in Accounts Payable26.973.5545.9439.197.88
Change in Other Working Capital47.3514.77-0.26-10.05-6.36
Other Operating Activities47.3572.140.11-56.5376.23
Net Cash from Operating Activities-306.20-467.36-495.70-417.65-271.55
Investing Activities
Capital Expenditures-1.432.44-14.49-23.70-19.86
Acquisitions0.000.000.00-10.190.00
Purchases of Investments7.35288.8766.69-86.35-274.70
Sales/Maturities of Investments7.35288.87280.53-0.53-1.69
Other Investing Activities0.95288.879.54-0.535.05
Net Cash from Investing Activities6.88286.4761.73-110.58-291.20
Financing Activities
Debt Repayment-11.37-10.44-6.36-6.43-4.77
Common Stock Issued309.9110.295.15379.42607.42
Common Stock Repurchased0.00-1.81-105.31-21.610.00
Other Financing Activities-19.29134.440.00-21.61-31.37
Net Cash from Financing Activities443.93134.29396.77351.39602.65
Summary
Effect of Forex Changes on Cash22.77-6.0135.6938.59-53.49
Net Change in Cash144.61-46.60-1.50-138.25-13.59
Cash at Beginning of Period392.16444.77446.27584.52598.11
Cash at End of Period559.54392.16409.07407.68584.52
Free Cash Flow-307.62-469.75-510.19-441.35-291.41
Supplemental Disclosures
Interest Paid15.2115.679.291.841.50
Income Taxes Paid5.514.470.00-0.15-1.10